TIMP1 and colorectal carcinoma: In summary, the findings from this study revealed the anticancer activities of RV59 in CRC, and highlight additional avenues for RV59 as a potential treatment for CRC chemotherapy and resistance to targeted therapy, particularly by targeting the MYC/CXCL8/TIMP1 signaling pathway.